Private bio/pharma funding in 2025 totaled approximately $40.0 B  across 1,045 private funding events, slightly below 2024’s $40.4 B , but substantially below 2024’s 1,367  deals (FN1). Activity was heavily front-loaded, with January 2025  alone accounting for $6.3 B  and 138 deals , the single most active month of the year.  After a mid-year lull in deal volume and capital deployment, the market saw modest late-year momentum, particularly in October ($6.0 B) and December ($3

After a difficult 3 years of private biotech funding for early-stage biotech companies (FN1, FN2), we predict that 2026 will be a breakout year. Why? Public smid-cap biotech stocks soared in the 2nd half of 2025; Historical data shows that when public smid-cap biotech stocks soar, the biotech IPO market opens up the following year; Once the biotech IPO market opens, private funding should follow in subsequent quarters Public smid-cap biotech stocks soared in the 2nd half of 2

After more than 25 years working with biotech innovators, I’ve learned that the real value of a patent family lies in the inventive scope where your science, legal strategy, and innovation truly meet . That intersection is what I call the patent sweet spot . So, what exactly is the sweet spot? It’s the range of claim scope that matches the working examples in your application — broad enough to protect what matters commercially, but grounded enough in data to avoid overreach

Innovation, collaboration, and thoughtful IP strategy, that’s what built Invitrogen’s success. And it’s still what drives the best biotech companies today. In 2004, I joined Invitrogen , one of the most dynamic biotech companies of its time. Recently, I came across my old Invitrogen catalog from that year, a snapshot of the start of the company’s golden era, and it brought back a flood of memories. The catalog reads like a roll call of transformative tools: Lipofectamine, Su